LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Затворен

СекторЗдравеопазване

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-0.05% downside

Настроения в новините

By Acuity

67%

33%

309 / 351 Класиране в Healthcare

Mirati Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.02.2026 г., 23:21 ч. UTC

Придобивния, сливания и поглъщания

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15.02.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Falls on Possible Position Adjustments -- Market Talk

15.02.2026 г., 23:06 ч. UTC

Печалби

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Shareholders to Receive A$5.20/Share in Cash

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO Tania Archibald Speaking on a Call With Media

15.02.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15.02.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15.02.2026 г., 20:48 ч. UTC

Печалби

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15.02.2026 г., 20:47 ч. UTC

Печалби

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15.02.2026 г., 20:46 ч. UTC

Печалби

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15.02.2026 г., 20:45 ч. UTC

Печалби

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15.02.2026 г., 20:43 ч. UTC

Печалби

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope Net Debt A$2.2 Million at Dec. 31

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15.02.2026 г., 20:41 ч. UTC

Печалби

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15.02.2026 г., 20:39 ч. UTC

Печалби

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Сравнение с други в отрасъла

Ценова промяна

Mirati Therapeutics Inc Прогноза

Ценова цел

By TipRanks

-0.05% надолу

12-месечна прогноза

Среден 58.67 USD -0.05%

Висок 59 USD

Нисък 58 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Mirati Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Mirati Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

309 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.